AstraZenecaAZN
AZN
About: A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Employees: 94,300
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
39% more call options, than puts
Call options by funds: $491M | Put options by funds: $354M
6% more first-time investments, than exits
New positions opened: 157 | Existing positions closed: 148
0.85% more ownership
Funds ownership: 32.25% [Q3] → 33.1% (+0.85%) [Q4]
1% less repeat investments, than reductions
Existing positions increased: 420 | Existing positions reduced: 424
1% less funds holding
Funds holding: 1,212 [Q3] → 1,195 (-17) [Q4]
13% less capital invested
Capital invested by funds: $39B [Q3] → $34.1B (-$4.9B) [Q4]
19% less funds holding in top 10
Funds holding in top 10: 16 [Q3] → 13 (-3) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for AZN.
Financial journalist opinion
Based on 54 articles about AZN published over the past 30 days
Negative
CNBC
21 hours ago
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Negative
Proactive Investors
1 day ago
AstraZeneca's quarterly earnings may undershoot; tariffs and a trade war pose the bigger obstacle
AstraZeneca PLC (LSE:AZN) is due to report first-quarter earnings on April 29, and UBS is bracing for a modest miss against market expectations, though the bank maintains a broadly supportive stance on the UK-listed drugmaker. Analysts at the Swiss investment bank expect group revenue and core operating profit to come in around 1% and 2% below Visible Alpha consensus, respectively, with softer-than-expected sales from diabetes drug Farxiga and rare disease treatment Soliris weighing on performance.
Neutral
Zacks Investment Research
1 day ago
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.
Negative
Proactive Investors
2 days ago
AstraZeneca and GSK retain defensive qualities, but tariff assault on sector could change that
UBS has warned that drugmakers such as AstraZeneca and GSK could be among the most exposed in Europe's pharmaceuticals sector should President Trump follow through on threats to impose new levies on the industry, despite medicine currently being exempt from trade tariffs. In a detailed report analysing potential flashpoints for investors, the Swiss bank argues that while the European sector as a whole remains a defensive play in a possible global downturn, key companies could face pressure from changes to US tax policy and regulatory disruption.
Positive
CNBC
2 days ago
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties on goods from China to 125% and citing a "lack of respect.
Neutral
CNBC Television
2 days ago
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Negative
Seeking Alpha
2 days ago
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturing, companies like Eli Lilly and Novo Nordisk are suffering substantial share price declines. The feasibility of relocating drug manufacturing to the U.S. is highly questionable, potentially leading to drug shortages and higher domestic prices.
Negative
Reuters
2 days ago
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm to patients.
Negative
CNBC
2 days ago
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Negative
WSJ
2 days ago
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Charts implemented using Lightweight Charts™